[Thromboxane A2 metabolism and clinical effects of selective thromboxane A2 synthetase inhibitor in patients with chronic glomerulonephritis].
Niwa
T
T
Nomura
T
T
Ozawa
Y
Y
Maeda
K
K
Shibata
M
M
D000179:Acrylates / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008297:Male; D008689:Methacrylates / Q000627:therapeutic use*; D013928:Thromboxane A2 / Q000378:metabolism*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000179:Acrylates; D008689:Methacrylates; D013928:Thromboxane A2; D013930:Thromboxane-A Synthase; C034364:ozagrel